Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Congratulations skyyy...you've been calling this one right on target all along. Your insights on the short attack, when ACEL was over-sold and your TA throughout has been great. I'm following you on this one all the way to a new 52-week high ($3.74). I'm back in buying more...IMO it's poised to take off!
Anybody still following CSBR? ....IMO it is a strong buy here, or time for re-entry. I was blown away by the two-cents/share earnings...I've NEVER seen that from a start-up biotech!!
skyyy...as the 2.5 million short shares scramble to cover as ACEL moves higher it will fuel a strong rally IMO....
skyyy....I think the move on ACEL is simply the shorts getting out of the way. This stock has wanted to go higher for weeks and has been under a fierce highly organized short attack, which seems to be over. There must be around 2.5 million short shares out there. As the stock moves higher covering the shorts will fuel a strong rally IMO...
skyyy...my read on the ACEL move is simple...the short attack has subsided at least for now. It looks like the short attack could be over...as the stock moves higher covering the over 2,000,000 shorts will fuel a rally. Strong Buy IMO
Very nice two day bounce for ACEL
Another good article for PKTX...ProtoKinetix is ahead of Novocell on this....
http://www.msnbc.msn.com/id/23259462/
Very interesting article for PKTX....
http://www.msnbc.msn.com/id/15285941/
apparently the link I just provided changes its story everyday...I'll try to find the article...
Interesting article for PKTX...national news on cord blood stem cells that could save child....
http://www.msnbc.msn.com/id/3041426/
Looking ahead on ACEL....When ACEL gets FDA approval, which IMO should be within a year, it should run to at least $40. Given contracts already in place they will have earnings of $2/share...at a PE of 30 the stock is between $40 and $60......To illustrate a recent comparison, in August, 2006 ACOR's stock price was $2. Two months later the stock price was $22. It rose to a high of roughly $27 in May, 2007 and is currently trading over $17.
What moved the stock price so dramatically from $2 to over $20 in the fall of 2006? On September 26, 2006 ACOR issued a press release reporting positive results of the Phase III trial of its drug candidate ... Fampridine-SR ... to improve walking capabilities in patients with MS. The PR news of positive Phase III trial results for this drug literally moved the stock price of ACOR from $2 to $20 in two months.
Unlike ACEL ... ACOR does not have "fast track" or " orphan drug " status with the FDA. ACOR is now conducting the Phase IIIB trial of the drug for any cardiovascular effects. This won't be completed until mid 2008. The FDA is not expected to rule on any NDA until sometime in 2009. Yet ACOR's stock rose from $2 to $20 in two months after the press release of positive Phase III results in September of 2006 ... and is still trading over $17 today. Barron's estimates that annual sales of the drug could approach $500 million/year within 5 years of any FDA approval. Barron's rates ACOR as a BUY at the current price ... as it moves toward a possible FDA decision in the next 2 years. The market for ONCONASE is substantially more lucrative and FDA approval for ACEL could be forthcoming much sooner.
The relevance of this summary above to ACEL is very important IMO in properly understanding ACEL's " Share Price Potential " from this point on. If ACOR"s stock can soar from $2 to $20 simply on the reporting and publicizing of positive Phase III trial results ... what can ACEL's stock price achieve if it properly announces and publicizes positive Phase IIIB trial results for ONCANASE?
When ACEL gets FDA approval, which should be within a year, it should run to $40. Given contracts already in place they will have earnings of $2/share...at a PE of 30 the stock is between $40 and $60......Additionally, in August, 2006 ACOR's stock price was $2. Two months later the stock price was $22. It rose to a high of roughly $27 in May, 2007 and is currently trading over $17.
What moved the stock price so dramatically from $2 to over $20 in the fall of 2006? On September 26, 2006 ACOR issued a press release reporting positive results of the Phase III trial of its drug candidate ... Fampridine-SR ... to improve walking capabilities in patients with MS. The PR news of positive Phase III trial results for this drug literally moved the stock price of ACOR from $2 to $20 in two months.
Unlike ACEL ... ACOR does not have "fast track" or " orphan drug " status with the FDA. ACOR is now conducting the Phase IIIB trial of the drug for any cardiovascular effects. This won't be completed until mid 2008. The FDA is not expected to rule on any NDA until sometime in 2009. Yet ACOR's stock rose from $2 to $20 in two months after the press release of positive Phase III results in September of 2006 ... and is still trading in the low $20's today. Barron's estimates that annual sales of the drug could approach $500 million/year within 5 years of any FDA approval. Barron's rates ACOR as a BUY at the current price ... as it moves toward a possible FDA decision in the next 2 years.
The relevance of this summary above to ACEL is very important IMO in properly understanding ACEL's " Share Price Potential " from this point on. If ACOR"s stock can soar from $2 to $20 simply on the reporting and publicizing of positive Phase III trial results ... what can ACEL's stock price achieve if it properly announces and publicizes positive Phase IIIB trial results for ONCANASE?
Many thanks, skyyy...good summary, however, I would disagree with one part of it...when ACEL gets FDA approval, which should be within a year, it should run to $40 (you suggested it would be a $20+ stock). Given contracts already in place they will have earnings of $2/share...at a PE of 30 the stock is between $40 and $60......Additionally, in August, 2006 ACOR's stock price was $2. Two months later the stock price was $22. It rose to a high of roughly $27 in May, 2007 and is currently trading at about $22.
What moved the stock price so dramatically from $2 to over $20 in the fall of 2006? On September 26, 2006 ACOR issued a press release reporting positive results of the Phase III trial of its drug candidate ... Fampridine-SR ... to improve walking capabilities in patients with MS. The PR news of positive Phase III trial results for this drug literally moved the stock price of ACOR from $2 to $20 in two months.
Unlike ACEL ... ACOR does not have "fast track" or " orphan drug " status with the FDA. ACOR is now conducting the Phase IIIB trial of the drug for any cardiovascular effects. This won't be completed until mid 2008. The FDA is not expected to rule on any NDA until sometime in 2009. Yet ACOR's stock rose from $2 to $20 in two months after the press release of positive Phase III results in September of 2006 ... and is still trading in the low $20's today. Barron's estimates that annual sales of the drug could approach $500 million/year within 5 years of any FDA approval. Barron's rates ACOR as a BUY at the current price ... as it moves toward a possible FDA decision in the next 2 years.
The relevance of this summary above to ACEL is very important IMO in properly understanding ACEL's " Share Price Potential " from this point on. If ACOR"s stock can soar from $2 to $20 simply on the reporting and publicizing of positive Phase III trial results ... what can ACEL's stock price achieve if it properly announces and publicizes positive Phase IIIB trial results for ONCANASE?
skyyy...where in your opinion does ACEL go from here; what timeframe and why?
skyyy...where in your opinion does it go from here; what timeframe and why?
....tradingday.com is a comprehensive, reliable source with an extremely strong track record of accuracy. In this case, however, I think they're off by 20%...ACEL is a 100% super strong buy IMO. The triple play is stronger than ever: great chart on a breakout; short squeeze getting tighter; huge news coming soon...add to this that the sellers have dried up.
skyyy...the short squeeze on ACEL seems like Dejavu...I swear this happened once before with this stock...are you aware if it did and if so what were the details and what happened? (sorry if I'm remembering this wrong...)
Gordon, I know you've been watching ACEL lately...if you don't mind, I would like to give you my latest two cents...what I'm seeing with ACEL is the last of the sellers getting out of the way. As I stated in a previous post it was clear that the selling was drying up. If this continues, there is a strong short squeeze that will begin coming into play and we'll see a steady climb to $3.
What makes this so exciting, IMO, is that it appears that this upward trend is now perfectly timed for the upcoming huge phase III news. My only previous concern was that the imminent huge news would hit before the stock got traction and the bounce on the news would have been somewhere between $2.90 and $3.50. This was prior to learning from the board's CC on Friday that there have only been an additional two "evaluable events" since the late January update of 311. (Which is also a great indication that patients using ONCONASE are living much longer)
I thought they would have hit the magic 316 by now and that the news would have come out thus giving us a move to a high of $3.50. It now has time to build. This breakout combined with a delay in the huge news and fueled by the short squeeze easily puts ACEL over $4, IMO, on the announcement that the company is proceeding with the NDA. I don't think this is the least bit overly optimistic...I wouldn't be surprised to see $4.50 maybe it touches $5.
skyyy...what I'm seeing with ACEL is the last of the sellers getting out of the way. As I previously stated it was clear that the selling was drying up. If this continues, the short squeeze will begin coming into play and we'll see a steady climb to $3.
What makes this so exciting, IMO, is that it appears that this upward trend is now perfectly timed for the upcoming huge phase III news. My only previous concern was that the imminent huge news would hit before the stock got traction and the bounce on the news would have been somewhere between $2.90 and $3.50. This was prior to learning from the board's CC on Friday that there have only been an additional two "evaluable events" since the late January update of 311. (Which is also a great indication that patients using ONCONASE are living much longer)
I thought they would have hit the magic 316 by now and that the news would have come out thus giving us a move to a high of $3.50. It now has time to build. This breakout combined with a delay in the huge news and fueled by the short squeeze easily puts ACEL over $4, IMO, on the announcement that the company is proceeding with the NDA. I don't think this is the least bit overly optimistic...I wouldn't be surprised to see $4.50 maybe it touches $5. Sorry for the long response, but you asked.....
While Friday's nickel pullback was disappointing, IMO it was related to the overall weak market most of the week and especially on Thursday and Friday as well as the fact that it has had steady gains for a month. I'm still very bullish.
ACEL's CEO bought 250,000 shares at $2.18 on Wed 3-5-08. Just reported in new SEC form 4 filings. This is bullish news; look for upward move this week, IMO.
ACEL's CEO bought 250,000 shares at $2.18 on Wed 3-5-08. Just reported in new SEC form 4 filings. This is bullish news; look for strong upward move this coming week.
PKTX Golden Cross!!!
50 DMA is crossing up and over the 200 DMA!!!
Continued sharply higher stock price from here is coming IMO!!!
First commercial deal PR puts PKTX over $1.00+!!!
IMO ACEL's board will have more to say beyond the release of financials today. I wonder if they will update the total number of events if it's still less than 316....
This stock has been unbelieveable in recent weeks...the buy rating has been between 88% and 100%...still at 96% what does that tell us.....strong buy here....spread the word
Investors paying attention will buy on this news. Alfacell has plenty of cash to get though FDA approval. ONCONASE is clearly effective...I remember when news on the 316th event was expected by the end of September, then the end of last year...patients are obviously living longer than even Alfacell anticipated. If ACEL announces that they're filing the NDA after analyzing the data it means that Sidransky and Co. are convinced FDA approval is forthcoming
Very relevent point, skyyy. Investors paying attention will buy here, not sell. Alfacell has plenty of cash to get though FDA approval. ONCONASE is clearly effective...I remember when news on the 316th event was expected by the end of September, then the end of last year... If ACEL announces that they're filing the NDA after analyzing the data it means that Sidransky and Co. are convinced FDA approval is forthcoming.
Everybody knows the financials suck right now; I'm hoping the market ignores this filing. The big news on phase III trials is imminent. IMO anyone selling ACEL here is making a costly mistake.
....thanks, I did
million...ACEL has a triple play working; the chart and TA is great including the fact that it's over sold; huge news is imminent, and thirdly a short squeeze will fuel the rally. Super strong buy here IMO
skyyy...ACEL has a triple play working; the chart and TA is great including the fact that it's over sold; huge news is imminent, and thirdly a short squeeze will fuel the rally. Super strong buy here IMO
For those of you following PKTX, here's my two cents: Early stage biotechs don't go after government contracts without a deep pocket partner because they have to give up too much control and future interest. With Ed Martin and Don Weber working together (see recent news), I see wide open doors to the Department of Defense, Homeland Security, CDC and NIH. The point is, these heavyweights wouldn't be involved, IMO, unless they believe that financing, a 7-figure cash deal, or a big pharma partner is secured.
Early stage biotechs don't go after government contracts without a deep pocket partner because they have to give up too much control and future interest. With Ed Martin and Don Weber working together, I see wide open doors to the Department of Defense, Homeland Security, CDC and NIH. The point is, these heavyweights wouldn't be involved, IMO, unless they believe that financing, a 7-figure cash deal, or a big pharma partner is secured.
PKTX @ .51 on decent volume; looks like it might be ready for a nice move up...can anybody offer their TA on this one?
PKTX @ .51 on decent volume; looks like it might be ready for a nice move up...can anybody offer their TA on this one?
....good point
BTW...everybody needs to go to www.logisticshealth.com and check out Don Weber and his company. If you do, anything I say here will not do it justice. Check out LHI and pass along the link and the PKTX story to everybody...
I encourage everybody to accumulate now and then contact relatives, friends and anybody you owe a favor or want to do a favor for, and convince them to accumulate PKTX. The problem with many IHub traders is that they have no patience; many are momentum traders, some are day traders. In the case of PKTX, IMO, they are losing out. Hang in there and you will be rewarded...I'm not talking about a long time...IMO investors who wait only four to six months will be well rewarded; longs will cash in even more...something is developing here.....
my targets have been steady for several weeks...I see PKTX conservatively at $1.50-$2.00 in the short-term. You asked my target based upon today's news....I wouldn't say that my target is based upon Don Weber joining the company but because ProtoKinetix has made it clear, IMO, that something big is in the works. Weber's involvement helps confirm this point of view. This is beyond any hype...Dr. Ed Martin and Don Weber are heavyweights that are not speculating...IMO they KNOW what's going on and it must be substantial or they wouldn't be putting their names and reputations on the line.....
my targets have been steady for several weeks...I see PKTX conservatively at $1.50-$2.00 in the short-term. You asked my target based upon today's news....I wouldn't say that my target is based upon Don Weber joining the company but because ProtoKinetix has made it clear, IMO, that something big is in the works. Weber's involvement helps confirm this point of view. This is beyond any hype...Dr. Ed Martin and Don Weber are heavyweights that are not speculating...IMO they KNOW what's going on and it must be substantial or they wouldn't be putting their names and reputations on the line.....